Parastou Tizro, M.D.

626-256-4673
Parastou Tizro, M.D.
Pathologist
Clinical Expertise
  • Hematopathology
Academic Appointments
  • Assistant Clinical Professor, Department of Pathology
Clinical Teams
Pathology

Parastou Tizro, M.D., is a hematopathologist at City of Hope® Cancer Center Duarte, where she provides accurate and rapid diagnoses for patients with blood disorders and lymphomas, helping them receive the most targeted, effective cancer treatment plans possible.

Dr. Tizro earned her medical degree at Tabriz University of Medical Sciences in Iran. She then completed a residency in pathology at George Washington University in Washington, D.C., followed by a two-year hematopathology fellowship at City of Hope and advanced training in molecular genetics at Cedars-Sinai Medical Center in Los Angeles.

In addition to her clinical work, Dr. Tizro has published more than a dozen papers in peer-reviewed journals and two book chapters. During her residency, she was recognized as resident of the year two years running and honored as Best Researcher of the Year.

Dr. Tizro’s takes a collaborative, respectful approach to working with her patients, unraveling complex diagnostic puzzles to make a difference in their cancer journeys.

Location

Education & Experience

Degrees

  • 2009, Doctor of Medicine, Tabriz University of Medical Sciences, School of Medicine, Tabriz, Iran

Fellowship

  • 2024, Molecular Genetic, Cedars-Sinai Medical Center, Los Angeles, California
  • 2022, Hematopathology, City of Hope Comprehensive Cancer Center, Duarte, California

Residency

  • 2021, Pathology, George Washington University, Washington, D.C.

Professional Experience

  • 2024-Present, Assistant Clinical Professor, Department of Pathology, City of Hope, Duarte, California

Publications

  • Tizro P, Crisan L, Gaal K, Rosen ST, Zain J, Querfeld C. Mogamulizumab-associated lymphadenopathy masquerading as lymphoma progression. JAAD Case Rep. 2026 Feb 4;70:178-183. doi: 10.1016/j.jdcr.2026.01.046. PMID: 41859422; PMCID: PMC12996701. https://pubmed.ncbi.nlm.nih.gov/41859422/
  • Khanlari M, Wang W, Tizro P, Eldomery MK. The immunophenotypic and genetic characterization of pediatric T-lymphoblastic leukemia with a mature immunophenotype. Haematologica. 2026 Feb 1;111(2):751-755. doi: 10.3324/haematol.2025.288233. Epub 2025 Aug 28. PMID: 40874330; PMCID: PMC12862295. https://pubmed.ncbi.nlm.nih.gov/40874330/
  • Tizro P, Vail E, Paquette R, Eno CE. Identification of Rare PML::RARA Variant Missed by Traditional Molecular Testing, CAP Today, 2025. https://www.captodayonline.com/identification-of-rare-pmlrara-variant-missed-by-traditional-molecular-testing/
  • Tizro P, Chang L, Salhotra A, Arias-Stella J, Telatar M, Tomasian V, Gaal K, Song J, Soma L, Fuentes S, Garcia L, Fei F, Munteanu A, Marcucci G, Afkhami M. Novel NUTM1 Fusions in Relapsed Acute Myeloid Leukemia: Expanding the Genetic and Clinical Landscape. Int J Mol Sci. 2025 Dec 2;26(23):11676. doi: 10.3390/ijms262311676. PMID: 41373823; PMCID: PMC12692335. https://pubmed.ncbi.nlm.nih.gov/41373823/
  • Hughes JM, Song JY, Lee WY, Danilov AV, Mei MG, Ma H, Tizro P, Danilova OV, Soma LA. Peripheral blood plasmablasts, a potential confounder in chronic lymphocytic leukemia measurable residual disease analysis. Cytometry B Clin Cytom. 2025 Nov 4. doi: 10.1002/cyto.b.22263. Epub ahead of print. PMID: 41186049. https://pubmed.ncbi.nlm.nih.gov/41186049/
  • Jasim A, Lee W, Ma H, Quirk E, Song J, Hwee S, Hughes J, Tizro P, Soma L. CD9: Differential expression of normal bone marrow cellular components and leukemic myeloid blasts. Am J Clin Pathol. 2025 Nov 19;164(5):694-703. doi: 10.1093/ajcp/aqaf087. PMID: 40972677; PMCID: PMC12629872. https://pubmed.ncbi.nlm.nih.gov/40972677/
  • Fei F., Telatar M., Tomasian V., Chang L., Danilova O., Arias-Stella J., Pillai R., Soma L., Tizro P., Becker P. S., Stein A. S., Marcucci G., Afkhami M. et al Genetic characteristics of blastic plasmacytoid dendritic cell neoplasm: A single institution experience. Oncotarget. 2025; 16: 495-507. Retrieved from https://www.oncotarget.com/article/28742/text/
  • Fei F, Jariwala A, Pullarkat S, Loo E, Liu Y, Tizro P, Ali H, Otoukesh S, Amanam I, Artz A, et al. Genomic Landscape of Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Central Study. International Journal of Molecular Sciences. 2024; 25(18):10214. https://doi.org/10.3390/ijms251810214
  • Aldoss I, Tizro P, Bedi D, Mangan JK, Clark MC, Spencer D, Song JY, Cherian S, Pillai R, Kim Y, Mahajan N, Gendzekhadze K, James M, Jacobs K, Davidson-Moncada J, Forman SJ, Wang HY, Afkhami M. Myeloid lineage switch following CD7-targeted chimeric antigen receptor T-cell therapy in relapsed/refractory T-cell acute lymphoblastic leukemia. Haematologica. 2023 Dec 1;108(12):3511-3516. doi: 10.3324/haematol.2023.283566. PMID: 37470155; PMCID: PMC10690902.
  • Abdulbaki R, Tizro P, Boland JL, Zonouz TH, Aggarwal A, Nava VE. Chronic neutrophilic leukemia associated with thrombocytosis and a CSF3R Q781* nonsense mutation. International Journal of Laboratory Hematology. 2023;45(3):e79-e82. doi:10.1111/ijlh.14015
  • Mehdipor Dalivand M, Tizro P, Partain J, Aggarwal A, Lichy J, Ara FM, Nava VE. (2022). “Concurrent B Cell Acute Lymphoblastic Lymphoma/Leukemia and Monoclonal B Cell Lymphocytosis: A Case Report with Extensive Molecular Analysis.” Case Reports in Hematology, 2022.
  • Akhlaq H, Tizro P, Aggarwal A, Nava VE. “ABO Blood Group Association With COVID-19 Mortality” Journal of Hematology 11 (3), 121-122
  • Abdulbaki R, Tizro P, Bolnad JL, Hashemi Zonouz T, Aggarwal A, Nava VE. “Chronic neutrophilic leukemia associated with thrombocytosis and a CSF3R Q781* nonsense mutation” https://doi.org/10.1111/ijlh.14015
  • Abdulbaki R, Tizro P, Nava VE, Gomes da Silva M, Ascensão JL. “Low-Grade Primary Splenic CD10-Positive Small B-Cell Lymphoma/Follicular Lymphoma” Current Oncology. 2021; 28(6):4821-4831. https://doi.org/10.3390/curroncol28060407
  • Mehdipour Dalivand M, Tizro P, Aggarwal A, Nava VE. Increased CD23 expression in postsplenectomy polyclonal B-Cell lymphocytosis. Int J Lab Hematol. 2022 Feb;44(1):e32-e35. doi: 10.1111/ijlh.13688. Epub 2021 Aug 26. PMID: 34448336.
  • Tizro P, Liu ML, Aggarwal A, Nava VE. “ABO Blood Group as a Prognostic Factor in Patients with Diffuse Large B Cell Lymphoma” Clin Lymphoma Myeloma Leuk. 2020 Mar 16:S2152-2650(20)30134-8.
  • Alizadeh V, Kazemihaki B, Eftekhari J, Tizro P. “Comparison of pain on propofol injection with three methods: mixed lidocaine with Propofol, propofol after lidocaine injection and purified one percent propofol injection.” JAP 2014;4(3):30-37